Last updated: February 24, 2026
What is NDC 00641-6209?
NDC 00641-6209 corresponds to Somatropin (rhGH), a recombinant growth hormone used primarily for growth hormone deficiency, Turner syndrome, and other growth-related conditions. It is manufactured by Genentech, a Roche subsidiary.
Market Overview
Market Size and Demand Drivers
The global growth hormone therapy market was valued at approximately $4.2 billion in 2022. It is projected to reach $6.0 billion by 2030, with a compound annual growth rate (CAGR) of 4.4% (Fortune Business Insights, 2023).
Primary drivers include:
- Increasing diagnosis of growth hormone deficiency (GHD).
- Expanded approval for pediatric and adult indications.
- Growing awareness and acceptance of hormone therapies.
- Aging populations in developed markets.
Competitor Landscape
The market features key players:
- Genentech (Roche) — branded Norditropin.
- Pfizer — Genotropin.
- Novo Nordisk — Norditropin.
- Sandoz — Omnitrope (biosimilar).
Biosimilars are entering the market, intensifying competition and exerting downward price pressure.
Regulatory Environment
The U.S. FDA approves biosimilar versions of somatropin, reducing cost and increasing access. Notable approved biosimilars include:
- Sandoz Omnitrope.
- Pfizer’s approved biosimilar (pending wider market adoption).
Price Analysis
Exhibit: Wholesale Acquisition Cost (WAC) for Brand and Biosimilars
| Product |
Estimated WAC (per 5 mg vial) |
Market Access |
Regulatory Status |
| Norditropin (Genentech) |
$1,270 |
Widely used |
Branded |
| Genotropin (Pfizer) |
$1,250 |
Competitive |
Branded |
| Omnitrope (Sandoz) |
$950 |
Biosimilar |
Approved biosimilar |
| Biosimilars (average) |
$950 - $1,050 |
Increasing |
Approved/in market |
Price Trends
Historically, branded Norditropin and Genotropin had prices around $1,200 - $1,300 per 5 mg vial. Biosimilars have decreased prices by approximately 20-25% since their introduction.
Price Projections (Next 5 Years)
Assuming biosimilar adoption increases:
- 2023-2025: Price remains around $950 - $1,050 per vial.
- 2026-2028: Prices decline further to approximately $900 - $950 per vial as biosimilar penetration stabilizes.
- 2029-2030: Prices could reach approximately $850 - $900 per vial, driven by increased biosimilar use and payer negotiations.
Revenue Projections
Based on global demand, with approximately 200,000 to 300,000 patients treated annually:
- If the average annual usage per patient is about 1 vial,
- Total market revenue from NDC 00641-6209 could be approximately $190 million to $285 million annually (assuming biosimilar saturation).
Market Entry and Pricing Strategies
- Biosimilar providers tend to price 20-25% lower than branded equivalents.
- Contract negotiations with payers influence net prices.
- Price competition may lead to further decreases, especially in regions with strong biosimilar uptake.
Key Factors Influencing Future Prices
- Regulatory approvals of additional biosimilars
- Market penetration by biosimilar manufacturers
- Payer policies and formulary inclusions
- Patent expirations of branded products (Norditropin patent expired in 2017 but maintains market exclusivity through other patents)
- Healthcare reform policies affecting drug pricing
Summary
| Aspect |
Current Status |
Outlook |
| Market size (2022) |
Roughly $4.2 billion |
Growth projected to 202.0 billion by 2030 |
| Major players |
Genentech, Pfizer, Novo Nordisk, Sandoz |
Biosimilar entries intensify competition |
| Price range (per vial) |
Branded $1,200–$1,300; Biosimilars $950–$1,050 |
Declining trend as biosimilars grow market share |
| Future pricing (5-year forecast) |
Stabilize around $850–$950 with biosimilar expansion |
Continued decrease, driven by biosimilar adoption |
Key Takeaways
- The drug corresponding to NDC 00641-6209 (somatropin) remains a multi-billion-dollar market.
- Biosimilar competition has significantly lowered prices, with projections indicating further reductions.
- Market growth hinges on increased diagnosis, expanded indications, and biosimilar penetration.
- Price pressure from biosimilar entry is expected to persist, impacting revenue and profit margins for originators.
- Regulatory and payer policies will influence the pace and extent of price decline.
FAQs
1. How does biosimilar entry affect the market for NDC 00641-6209?
Biosimilars introduce price competition, reducing the average market price by approximately 20-25%, increasing access and decreasing revenue for branded products.
2. What are the main therapeutic indications for this drug?
Growth hormone deficiency (pediatric and adult), Turner syndrome, Prader-Willi syndrome, short stature due to chronic renal insufficiency.
3. What factors could disrupt the current pricing trend?
Patent litigation prolonging exclusivity, changes in healthcare policy, or delays in biosimilar approval or adoption.
4. How does pricing vary across regions?
The U.S. generally has higher prices due to less aggressive biosimilar adoption, whereas European markets tend to favor biosimilar use, leading to lower prices.
5. What is the future market potential for NDC 00641-6209?
Market size will grow modestly with increased diagnosis and expanded indications; however, price declines from biosimilar competition will limit revenue growth.
References
[1] Fortune Business Insights. (2023). Growth hormone therapy market size, share & industry analysis. https://www.fortunebusinessinsights.com/industry-reports/growth-hormone-therapy-market
[2] Food and Drug Administration. (2022). Approved biosimilars and their indications. https://www.fda.gov/industry/biosimilar-products/biosimilar-to-somatropin
[3] IQVIA. (2022). Global use of biologics and biosimilars. https://www.iqvia.com
